[177Lu]Lu-NeoB + [68Ga]Ga-NeoB
Phase 1Active 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Newly Diagnosed and Recurrent Glioblastoma
Conditions
Newly Diagnosed and Recurrent Glioblastoma
Trial Timeline
May 15, 2024 → Jul 1, 2032
NCT ID
NCT05739942About [177Lu]Lu-NeoB + [68Ga]Ga-NeoB
[177Lu]Lu-NeoB + [68Ga]Ga-NeoB is a phase 1 stage product being developed by Novartis for Newly Diagnosed and Recurrent Glioblastoma. The current trial status is active. This product is registered under clinical trial identifier NCT05739942. Target conditions include Newly Diagnosed and Recurrent Glioblastoma.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05739942 | Phase 1 | Active |
Competing Products
18 competing products in Newly Diagnosed and Recurrent Glioblastoma